Healthcare–associated Pneumonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033

Healthcare–associated Pneumonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033

Report Format: PDF+Excel | Report ID: SR112023A6681
Buy Now

The healthcare–associated pneumonia market has been comprehensively analyzed in IMARC’s new report titled Healthcare–associated Pneumonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033”. Healthcare-associated pneumonia (HCAP) refers to a type of pneumonia that occurs due to prior contact with a healthcare environment. It is associated with the presence of several risk factors, including hospitalization in the past, home infusion therapy, dialysis, residing in a nursing center, immunocompromised state, etc. Bacterial infection, as opposed to a virus, is the predominant source of this form of pneumonia. Most symptoms of healthcare-associated pneumonia are equivalent to those seen in pneumonia developed outside hospitals. This condition is characterized by unpleasantness, a sense of unease, reduced appetite, cough with greenish or mucus-like phlegm, abdominal discomfort, and difficulty in breathing. Some other symptoms include sharp chest pain that exacerbates with inhalation and exhalation or coughing, as well as diminished blood pressure and an increased heart rate. The diagnosis of healthcare-associated pneumonia begins with a chest x-ray or CT scan to inspect the lungs and arterial blood gases to measure respiratory rate. It is accompanied by a sputum culture to detect the microorganisms causing pneumonia and a pulse oximetry test to monitor blood oxygen levels. The diagnosis also involves bronchoscopy, which is essential to avoid the possibility of an incorrect prognosis.

The increasing prevalence of chronic ailments, such as cardiac arrest, brain stroke, kidney failure, etc., which require surgical intervention and prolonged hospital stays is primarily driving the global healthcare-associated pneumonia market. Additionally, the inflating number of patients admitted to medical facilities who have antibacterial resistance owing to the excessive usage of antibiotics is also positively influencing the market growth. Moreover, the escalating utilization of combination therapy to treat HCAP since it reduces the chances of resistance developed by the bacteria and provides a broad spectrum of coverage is also creating a positive outlook for the market. In addition to this, the widespread adoption of point-of-care testing products owing to their associated benefits, including convenience, quicker diagnosis, and improved patient outcomes, is acting as a significant growth-inducing factor. Furthermore, the ongoing development of resistant strains and the increasing resultant need for newer antibiotics are promoting extensive R&D activities. This, in turn, is also augmenting the global market. Besides this, the emerging popularity of multiplex PCR-based platforms for diagnosing healthcare-associated pneumonia, as it offers high detection efficiency, thereby reducing cost and time, is further propelling the market growth. Additionally, the rising emphasis of the key players on developing efficient vaccines and antibiotics by utilizing advanced clinical solutions is also expected to drive the global healthcare-associated pneumonia market in the coming years.

IMARC Group’s new report provides an exhaustive analysis of the healthcare–associated pneumonia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool forhealthcare–associated pneumonia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the healthcare–associated pneumonia market in any manner.

Time Period of the Study

  • Base Year: 2022
  • Historical Period: 2017-2022
  • Market Forecast: 2023-2033
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the healthcare–associated pneumonia market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the healthcare–associated pneumonia market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs

This report also provides a detailed analysis of the current healthcare–associated pneumonia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug overview
  • Mechanism of action
  • Regulatory status
  • Clinical trial results
  • Drug uptake and market performance
     

Late-Stage Pipeline Drugs

  • Drug overview
  • Mechanism of action
  • Regulatory status
  • Clinical trial results
  • Regulatory status
     

Key Questions Answered in this Report

Market Insights

  • How has the healthcare–associated pneumonia market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
  • What was the country-wise size of the healthcare–associated pneumonia market across the seven major markets in 2022 and what will it look like in 2033?
  • What is the growth rate of the healthcare–associated pneumonia market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the size of the healthcare–associated pneumonia patient pool (2017-2022) across the seven major markets?
  • What would be the forecasted patient pool (2023-2033) across the seven major markets?
  • What are the key factors driving the epidemiological trend of healthcare–associated pneumonia?
  • What will be the growth rate of patients across the seven major markets?
     

Healthcare–Associated Pneumonia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for healthcare–associated pneumonia drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the healthcare–associated pneumonia market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Healthcare–associated Pneumonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033
Select Licence Type



Benefits of Customization

Personalize This Research

Triangulate with your Data

Get Data as per your Format and Definition

Gain a Deeper Dive into a Specific Application, Geography, Customer or Competitor

Any level of Personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Clients Testimonial

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Bayer AH

It was indeed a great experience to work with IMARC on the assignment on Aqua market. The team had done a fantastic job in terms of what was expected, what was assured and what was the result… the report gave us many insights and market know how which allowed us to work on our strength and define exact strategies…

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More